Biosurgery Articles & Analysis
8 news found
InnovHeart s.r.l. announced today the appointment of David James Wilson, an experienced healthcare and medical device executive as Chief Executive Officer of the company and executive member of the Board of Directors. Mr. Wilson’s career spans over 30 years and includes broad, global leadership expertise in business strategy and operations, R&D, commercial readiness and product ...
During his tenure at Sanofi, he also served as Head, North America Business Development, Specialty Care, as well as Head of Biosurgery Business Development & Portfolio Strategy. Previously, Mr. ...
Endomedix announced today that it received a patent of 30 issued claims for its PLEXimine™ Polysaccharide Technology platform for a new class of biomaterials. The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. This technology platform ...
Endomedix is a private biotechnology company that has developed a patented platform technology that it will use to develop a series of biosurgery products. The first products from this platform will be a series of absorbable hemostats for surgical, military and first responder applications. ...
Endomedix is a private biotechnology company that has developed a patented platform technology that it will use to develop a series of biosurgery products. The first products from this platform will be a series of absorbable hemostats for surgical, military and first responder applications. ...
Endomedix is a private biotechnology company that has developed a patented platform technology that it will use to develop a series of biosurgery products. The first products from this platform will be a series of absorbable hemostats for surgical, military and first responder applications. ...
Endomedix, Inc., a developer of unique biosurgical products based on natural biopolymer systems, today announced it will provide the first public presentation of its work at a scientific meeting. The 2019 Annual Meeting is scheduled for April 3-6 in Seattle, Washington. The presentation will provide data and descriptions of the performance of its patented hydrogel biomaterial in a series of ...
Endomedix, Inc., a developer of unique biosurgical products based on its natural biopolymer systems, today announced that it has submitted a comprehensive patent application to protect both its latest chemistry technology and also the design and function of the spray-on hydrogel hemostat that it is developing for brain and spine surgery indications. This patent application further expands and ...